<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-107501</identifier>
<setSpec>0304-5013</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Outcome and intrauterine management of fetal tachycardia</dc:title>
<dc:description xml:lang="en">Objective. To review the intrauterine management and outcome of fetal tachycardia. Methods. A total of 23 fetuses with distinct types of tachycardia, diagnosed at a median gestational age of 30.2 weeks, were included. The inclusion criteria were fetal tachycardia diagnosed prenatally, and complete, long-term follow-up in utero and after birth in the Obstetrics Department, La Fe University Hospital, Valencia, Spain from 2002 to 2010. Data from included pregnancies were collected from a review of the patients&#146; medical records. Results. Of 23 fetuses with fetal tachycardia diagnosed in utero, 18 (78.26%) had supraventricular tachycardia, two (8.69%) had atrial flutter and three (13.04%) had tachycardia of unknown origin. Six fetuses (26.08%) developed hydrops. Of the 23 fetuses, 13 (56.52%) received digoxin, one (4.34%) digoxin with amiodarone, two (8.69%) digoxin with flecainide and one (4.34%) received flecainide alone. The initial treatment was adjusted in 15 fetuses (65.21%). The tachycardia was reverted in nine fetuses. Eleven pregnancies (47.82%) ended at full term by vaginal delivery. A cesarean section was performed in 12 women (52.17%). Conclusion. Our data are consistent with current evidence that a significant proportion of fetal tachycardias can be treated successfully by transplacental administration of antiarrhythmic drugs. The first-line treatment is digoxin, which can be associated with flecainide. The long-term prognosis for fetuses diagnosed with tachycardia is excellent, with the abnormal rhythm resolving spontaneously during pregnancy in a high percentage of cases (AU)</dc:description>
<dc:creator>Hidalgo-Mora, Juan José</dc:creator>
<dc:creator>Martínez-Varea, Alicia</dc:creator>
<dc:creator>Maiques, Vicente</dc:creator>
<dc:creator>Vila-Vives, José M</dc:creator>
<dc:creator>Perales-Marín, Alfredo</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. Revisar la evolución y las opciones terapéuticas en las gestaciones con diagnóstico intrauterino de taquicardia fetal. Materiales y métodos. Estudio observacional retrospectivo en 23 pacientes con diagnóstico de taquicardia fetal y seguimiento gestacional en el Servicio de Obstetricia del Hospital Universitario La Fe de Valencia entre los años 2002 y 2010. Los datos de las gestaciones incluidas en el estudio fueron recogidos mediante revisión de las historias clínicas de las pacientes. Resultados. La edad gestacional media de detección de la taquicardia fetal fue 30,2 semanas. De los 23 fetos, 18 (78,26%) presentaron taquicardia supraventricular, 2 (8,69%) flutter auricular y 3 (13,04%) taquicardia no filiada. Seis fetos desarrollaron hidrops (26,08%). En 13 casos (56,52%) se prescribió inicialmente tratamiento con digoxina en monoterapia, en uno (4,34%) con digoxina y amiodarona, en 2 (8,69%) con digoxina y flecainida y en otro (4,34%) únicamente con flecainida, debiendo modificarse el tratamiento inicial en 15 casos (65,21%). La taquicardia fue revertida en 9 fetos. Finalizaron mediante parto vaginal 11 gestaciones (47,82%), mientras que en las 12 restantes se realizó cesárea (52,17%). Conclusión. Nuestros resultados apoyan la evidencia actual, considerando que una proporción significativa de taquicardias fetales pueden ser tratadas exitosamente mediante administración transplacentaria de antiarrítmicos, siendo la digoxina el fármaco de primera elección. Con el tratamiento y el seguimiento adecuados el pronóstico fetal de esta afección es favorable, resolviéndose el ritmo cardiaco anormal en un alto porcentaje de casos durante la gestación (AU)</dc:description>
<dc:source>Prog. obstet. ginecol. (Ed. impr.);55(10): 495-500, dic. 2012.</dc:source>
<dc:identifier>ibc-107501</dc:identifier>
<dc:title xml:lang="es">Evolución y manejo intrauterino de las taquicardias fetales</dc:title>
<dc:subject>^d22261</dc:subject>
<dc:subject>^d11732^s22066</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d11732^s22045</dc:subject>
<dc:subject>^d23233^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d5429^s22053</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d5429^s29166</dc:subject>
<dc:subject>^d29399</dc:subject>
<dc:subject>^d29142^s22045</dc:subject>
<dc:subject>^d29142^s22066</dc:subject>
<dc:subject>^d5427^s22016</dc:subject>
<dc:subject>^d4116^s22073</dc:subject>
<dc:subject>^d13993^s22016</dc:subject>
<dc:subject>^d30449^s22073</dc:subject>
<dc:subject>^d5432^s22045</dc:subject>
<dc:subject>^d5432^s22039</dc:subject>
<dc:type>article</dc:type>
<dc:date>201212</dc:date>
</metadata>
</record>
</ibecs-document>
